Janney Montgomery Scott LLC increased its stake in West Pharmaceutical Services Inc. (NYSE:WST) by 25.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,055 shares of the medical instruments supplier’s stock after purchasing an additional 1,656 shares during the quarter. Janney Montgomery Scott LLC’s holdings in West Pharmaceutical Services were worth $1,142,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. Krane Funds Advisors LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at approximately $26,000. Steward Partners Investment Advisory LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at approximately $40,000. Machina Capital S.A.S. purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at approximately $42,000. Advisory Services Network LLC grew its stake in West Pharmaceutical Services by 84.5% in the 2nd quarter. Advisory Services Network LLC now owns 393 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 180 shares in the last quarter. Finally, FMR LLC grew its stake in West Pharmaceutical Services by 41.3% in the 1st quarter. FMR LLC now owns 794 shares of the medical instruments supplier’s stock valued at $88,000 after buying an additional 232 shares in the last quarter. 91.07% of the stock is currently owned by institutional investors.
A number of research analysts recently weighed in on the stock. Bank of America upgraded shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research note on Friday, July 26th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a research note on Sunday, November 3rd. Finally, ValuEngine lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $131.39.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.08. West Pharmaceutical Services had a net margin of 12.82% and a return on equity of 16.66%. The business had revenue of $456.10 million during the quarter, compared to analyst estimates of $450.03 million. During the same period in the previous year, the business earned $0.76 EPS. West Pharmaceutical Services’s revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts forecast that West Pharmaceutical Services Inc. will post 3.14 EPS for the current year.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Article: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.